Trials / Completed
CompletedNCT00277472
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan/Hydrochlorothiazide | 160/12.5 mg taken once daily orally |
| DRUG | HCTZ | 25 mg taken once daily orally |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2005-11-01
- First posted
- 2006-01-16
- Last updated
- 2011-06-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00277472. Inclusion in this directory is not an endorsement.